Ueberall 1999.

Study characteristics
Methods	Randomized, double‐blind, placebo‐controlled, 2‐way cross‐over trial of intranasal sumatriptan
Participants	Participants were < 10 years of age with migraine with or without aura per IHS 1988 criteria and at least 2 migraine attacks per month Randomized (N = 14); analyzed (N = 14)
Interventions	Each participant treated 1 migraine with intranasal sumatriptan (20 mg) or placebo. The second migraine was treated with the other medication.
Outcomes	Headache relief at 2 h Pain free at 2 h Headache recurrence Use of rescue medication Presence of nausea or vomiting within 4 h Adverse events Other reported outcomes: Presense of photophobia or phonophobia within 4 h Other time points (30, 60, 180, 240 minutes) Time to meaningful recovery Treatment preference
Headache severity scale	4‐point scale (none, mild, moderate, severe)
Funding source	Not specified
Publication	Journal
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was based on a computer algorithm. . ."
Allocation concealment (selection bias)	Unclear risk	Quote: "Patients were randomly assigned to two alternative treatment strata"; "access to treatment assignments were given to D.W., if necessary"
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "0.9% sodium chloride" used as placebo Comment: cross‐over trial; blinding likely maintained. Disturbance of taste reported both for sumatriptan and placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Data sufficient for analysis were provided by all 14 children".
Selective reporting (reporting bias)	Low risk	Comment: all outcomes reported